IRA & Medicare drug price negotiation
Most-Favored-Nation Drug Pricing Framework: How Manufacturer Agreements Affect Medicaid Best Price, Contracts, and Compliance
Frier LevittTopic alignment 90
The White House announced on August 31, 2026, that nine additional pharmaceutical manufacturers had signed most-favored-nation (MFN) pricing agreements with the federal government. The new signatories include Alcon, Astellas Pharma, BeOne Medicines, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva Pharmaceuticals, and UCB. With this third wave, the total roster of participating manufacturers has grown to… The post Most-Favored-Nation Drug Pricing Framework: How Manufacturer Agreements Affect Medica
Filed under
- IRA & Medicare drug price negotiationmatch 90
- CMMI modelsmatch 88
CMS Issues Final Rule on the Medicare Drug Price Negotiation Program and Medicare Prescription Drug Benefit Program
AMCP (Academy of Managed Care Pharmacy)Topic alignment 95
CMS finalizes rule to codify Medicare Drug Price Negotiation Program
AHATopic alignment 95
How the Biosimilars Access and Affordability Act Redefines IRA Delays
The Center for BiosimilarsTopic alignment 92
Medicare Part D Premiums and Cost Sharing in 2027
KFFTopic alignment 88